Holen Sie sich die Stockscreener-App
26.36
2.29%
0.59
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts - Yahoo Finance
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments - GuruFocus.com
Investors Purchase High Volume of Call Options on Pfizer (NYSE:PFE) - MarketBeat
Pfizer cost cutting leads to Tampa layoffs - The Business Journals
Pfizer gets FDA accelerated approval for Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment - Marketscreener.com
Pfizer to lay off 62 in Tampa - Business Observer
Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer - Business Wire
Pfizer (NYSE:PFE) Trading Up 1.6%What's Next? - MarketBeat
Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Phenobarbital Market CAGR of 5% Trends and Growth Analysis By 2024 to 2031 | Sanofi, Pfizer Inc., Novartis AG, - EIN News
Principal Financial Group Inc. Sells 1,349,308 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts - BioSpace
Judge Wrongly Axed $107M IP Verdict, Pfizer Tells Fed. Circ. - Law360
Why Pfizer (PFE) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Colleagues Celebrate Native American Heritage - Pfizer
Pfizer (NYSE:PFE) Trading 0.4% HigherTime to Buy? - MarketBeat
Liposomal Doxorubicin Market to Witness Massive Growth | Major Giants Pfizer, Ipsen, Johnson & Johnson - openPR
Is Pfizer Stock A Buy After Rallying On Its 2025 Guidance? - Investor's Business Daily
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26? - Yahoo Finance
PFIZER INC : Gets a Neutral rating from UBS - Marketscreener.com
Stomach Cancer Drugs Market Future Business Opportunities - openPR
Pfizer's SWOT analysis: stock outlook amid pipeline progress and cost cuts - Investing.com
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Jim Cramer’s Take on Pfizer (PFE): Can CEO Dr. Bourla’s Bold Strategy Overcome Debt and Turn the Stock Around? - Yahoo Finance
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis) (NYSE:PFE) - Seeking Alpha
Satellite Images Reveal Russian Military Movements in Syria - Yahoo Finance
Pfizer (NYSE:PFE) Shares Down 0.4% Following Analyst Downgrade - MarketBeat
Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call (PFE) - Seeking Alpha
Pfizer eyes 2025 revenue growth despite post-COVID challenges, activist pressure - MM+M Online
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations - Yahoo Finance
Pfizer reiterated at Market Perform by analyst following FY25 guidance - Investing.com Canada
Truist cuts Pfizer shares target, retains buy rating on growth projections - Investing.com
Pfizer: Jefferies confirms its analysis on the stock - Marketscreener.com
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy - Yahoo! Voices
Trending tickers: The latest investor updates on Pfizer, Micron, Nissan, Teva and National Grid - Yahoo Finance UK
Pfizer provides full-year 2025 guidance - The Pharma Letter
Pfizer aims to quell concern about its vaccine business under Trump - Crain's New York Business
Pfizer Sets 2025 Outlook, Confirms 2024 Guidance - Mirage News
Oncology Drugs Market Huge Growth in Future Scope 2024-2031 | - openPR
Epilepsy Drugs Market Detailed In New Research Report 2024 | - openPR
Pfizer Stock Jumps After Reassuring 2025 Guidance - The Wall Street Journal
Medicare Part D Redesign: Pfizer’s Catastrophic Phase Discounts Will Total $1.5bn In 2025 - Citeline News & Insights
Pfizer Confident On Policy Outlook Heading Into Trump Administration - Citeline News & Insights
Pfizer Stock Surges 4% on Reaffirmed Earnings Guidance, Don't Buy Shares Yet - Money Morning
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Trump: Will 'Knock Out' Pharma Middlemen - Marketscreener.com
Pfizer (NYSE:PFE) Trading Up 4%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Shares Gap UpStill a Buy? - MarketBeat
Trump ‘Middleman’ Remark Sinks CVS, UnitedHealth, Cigna Shares - MSN
Health Insurers Fall as Pfizer CEO Says Trump Wants PBM Reform - Yahoo Finance
Pfizer issues full-year 2025 guidance - Yahoo Finance
Pfizer does not expect major vaccine policy changes under Trump in 2025 - Reuters
Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For? - Yahoo Finance
Pfizer (PFE) technical analysisPfizer (NYSE:PFE) - Benzinga
Pfizer predicts stability, to Wall Street’s relief - BioPharma Dive
Global markets live: Meta Platforms, Pfizer, Broadcom, Nokia, Carlsberg... - Marketscreener.com
Pfizer earnings offer relief to weary investors - Crain's New York Business
Pfizer meets forecasts with 2025 guidance - ShareCast
Pfizer Shares Jump 4% on Positive 2025 Outlook Despite $1B Impact - Yahoo Finance
Pfizer Stock Rises as 2025 Outlook in Line With Expectations - Yahoo Finance
Pfizer’s In-Line Guidance Offers Relief to Weary Investors - Yahoo Finance
2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical - Schaeffers Research
UnitedHealth, CVS Health extend decline as Pfizer CEO cites Trump’s PBM comments - Seeking Alpha
Pfizer issues 2025 outlook in-line with Wall Street, shares rise - Yahoo Finance
Pfizer shares rise despite criticism Starboard, with optimistic 2025 earnings forecast - Marketscreener.com
Pfizer ticks up as expectation-matching guidance relieves investors - Proactive Investors UK
0.84%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):